Potential for Cell-Transplant Therapy with Human Neuronal Precursors to Treat Neuropathic Pain in Models of PNS and CNS Injury: Comparison of hNT2.17 and hNT2.19 Cell Lines
Figure 2
hNT2.17 and hNT2.19 cells are nontumorigenic: BrdU stain. hNT2.17 (a–c) and hNT2.19 (d–f) cells were exposed to 1 μM bromodeoxyuridine (BrdU) (a, d) during 3 days of proliferation or (b, c, e, f) for 1 week during differentiation in vitro. Proliferating cells (a, d) incorporate abundant BrdU during proliferation. Viable differentiated cells (b, e) were labeled with DAPI (4′6-diamidino-2-phenylindal-2HCl) stain, while the same field (c, f) of differentiated cells did not incorporate any BrdU during differentiation. After 2 weeks of treatment with retinoic acid (RA) and mitotic inhibitors, hNT2.17 and hNT2.19 cells cease dividing and differentiation proceeds without further cell division. Magnification bar = 20 nm (d); 30 nm (a, b, c, e, f).
